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First-generation biologics and ‘biosimilars’:
both are unique molecules
Recombinant biologic agents are proteins or peptides,
often similar to endogenous hormones, cytokines or anti-
bodies, derived using DNA technology (1). These pro-
teins fold into complex molecules whose architecture is a
key determinant of their function (Fig. 1) (2, 3). The
average molecular weight of a biologic ranges from
4000 Daltons (Da) for non-glycosylated proteins to
> 140 000 Da for monoclonal antibodies (4) and is
much greater than that of small molecule chemical phar-
maceuticals, whose average molecular weight ranges
from  160 to 800 Da (2). Recombinant biologic agents
are produced from cultured, genetically modiﬁed cell
lines and extracted through complex and lengthy puriﬁ-
cation procedures (2). As a consequence of their com-
plexity and cell-based production, biologic agents are
inherently more difﬁcult to characterise than standard
chemically derived agents (2, 3, 5). The properties of bio-
logic agents are dependent on their manufacturing pro-
cess, and even minor alterations at any one of the
numerous stages of production have the potential to
inﬂuence the end product (1–3). (See Mellstedt et al. (3)
for an evaluation of the steps involved in the manufac-
ture of biologics).
Historically, exclusivity expiry of standard small mole-
cule pharmaceutical agents has seen the development of
generic versions, which are exact copies of the innovator
product. Expiry of patents and data protection on ﬁrst-
generation biologics has, however, brought about a new
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ª 2011 John Wiley & Sons A/S 277situation; for the reasons discussed earlier, developing an
exact copy of a biologic agent is technically impossible
(1–3, 5, 6). For example, a ‘follow-on’ biologic agent will
not be manufactured using an identical process to the
innovator product, as this is proprietary knowledge
(3, 7). (See Kuhlmann and Covic (2) for a more detailed
discussion of the protein science of biologics). These
‘follow-on’ biologics are therefore unique molecules,
rather than identical generic copies of innovator biolo-
gics, and should be considered as such (3). The European
Medicines Agency (EMA) recognised this situation, stat-
ing that – ‘due to the complexity of biological⁄biotechnol-
ogy-derived products the generic approach is scientiﬁcally
not appropriate for these products’ (5) – hence a new reg-
ulatory pathway was needed. The term ‘biosimilar’ was
coined to refer to a product that is similar, but not iden-
tical, to the innovator biologic product (8).
Previous authors have reviewed the manufacturing and
approval process for biosimilars, speculating on what
issues might arise once such agents are introduced (1, 3,
9, 10). It is now 3 years since the ﬁrst biosimilars were
approved for use in Europe in the oncology⁄haematolo-
gy setting. Such agents have increased the prescribing
options open to physicians with regard to biologic medi-
cines. In this article, we seek to make physicians aware
of the general ongoing developments surrounding bio-
similars and to highlight speciﬁc issues that are pertinent
to their use in oncology clinical practice. The EMA
states that the decision to treat a patient with an innova-
tor or biosimilar medicine should be taken by a qualiﬁed
healthcare professional (8). Our intention is not to dis-
courage physicians from considering the use of biosimilar
products, but to highlight that they need to be informed
on biosimilar products with regard to marketing authori-
sation, extrapolation, labelling, substitution and pharma-
covigilance – in order to avoid complications and
problems associated with this new product class in gen-
eral and, more speciﬁcally, in oncology.
The regulation of biosimilars is an evolving
process
The European Union (EU) has led the way in the regula-
tion of biosimilars, responding to the patent and data
protection expiry of several innovator biologic medicines
in recent years (Fig. 2). The approval of ‘biosimilars’ by
regulatory bodies and coordinating authorities is a pro-
cess that is still evolving – both in the EU and around
the world.
European Medicines Agency
The EMA has established the ﬁrst regulatory framework
for assessing biosimilars. This is distinct from the process
required for generics (11, 12) and less extensive than the
process required for registration of a new biologic prod-
uct (13–16) or a new chemical product.
An overarching guideline deﬁnes the concept of bio-
similars and sets out the ‘comparability exercise’ through
which similarity between a biosimilar product and its ref-
erence innovator product must be demonstrated in order
to gain regulatory approval (5). The reference product
must be an innovator product, which is already author-
ised in the EU, with a similar active substance. Pharma-
ceutical form, strength and route of administration
should be the same as that of the reference product (5).
Comparability must be demonstrated in terms of quality,
efﬁcacy and safety (17,18). Comparability of quality is
Figure 1 Secondary, tertiary and quaternary structures of protein drugs. Adapted from: Kra ¨mer I & Jelkmann W. 2008 (92)
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nal product and must be demonstrated for analytical
methods, physico-chemical characterisation, biological
activity and purity of the similar biologic medicinal prod-
uct (17). Comparability of efﬁcacy is assessed via
non-clinical comparative in vitro and in vivo studies, and
a repeat-dose toxicology study of sufﬁcient length to
allow detection of relevant differences in toxicity (18).
Comparable clinical efﬁcacy is evaluated through a step-
wise procedure beginning with clinical pharmacokinetic
(PK) and pharmacodynamic (PD) studies, followed by
2- or 3-arm clinical efﬁcacy studies; in certain cases,
PK⁄PD studies alone may sufﬁce (18). Finally, clinical
safety should be evaluated in comparative clinical studies
assessing the adverse event proﬁle and immunogenicity.
Plans for postmarketing surveillance – pharmacovigilance
and risk management – should be provided (18).
The data requirements and studies necessary to dem-
onstrate comparability differ between product classes
and are laid out in speciﬁc guidelines for somatropin
(19), human soluble insulin (20), interferon alpha (21),
erythropoietins (22), granulocyte colony-stimulating fac-
tor (23), and most recently for biosimilar low molecular
weight heparins (24). Product classes currently under
consideration for speciﬁc guidelines include recombinant
follicle stimulation hormone, recombinant interferon beta
and monoclonal antibodies (25).
Food and Drug Administration
In March 2010, the US Congress passed legislation creat-
ing a legal pathway for biosimilars under the Patient
Protection and Affordable Care Act, as part of the wider
healthcare reform legislation (26). The legislation provid-
ing an approval pathway for biosimilar biological prod-
ucts is outlined in section ‘Title VII – Improving Access
to Innovative Medical Therapies: Subtitle A – Biologics
Price Competition and Innovation’. Biosimilarity is
established where the biological product is highly similar
to its reference product, notwithstanding minor differ-
ences in clinically inactive components, and there are no
clinically meaningful differences between the biological
product and the reference product in terms of the safety,
purity and potency of the product. The Food and Drug
Administration (FDA) will be responsible for reviewing
applications for biosimilarity.
World Health Organization
The World Health Organization (WHO) has also recog-
nised that the approach established for generic medicines
is not suitable for development, evaluation and licensing
of similar biotherapeutic products (SBPs) (27). In April
2010, the WHO Expert Committee on Biological Stan-
dardization published ﬁnal ‘Guidelines on Evaluation of
SBPs’, as part of its mandate to assure global quality,
safety and efﬁcacy of biotherapeutics (27). Similar to the
EMA, the WHO advocates a stepwise approach for the
licensing of an SBP that depends on demonstrated simi-
larity in quality, non-clinical and clinical parameters to a
suitable reference biotherapeutic product (RBP). The
RBP must be an innovator product of similar active sub-
stance, with the same dosage form and route of adminis-
tration, licensed on the basis of a full registration
dossier.
The comparability exercise between the SBP and the
RBP in the quality part represents an additional element
to the ‘traditional’ full quality dossier. Non-clinical eval-
uation of new biotherapeutics normally encompasses a
spectrum of PD, PK and toxicological studies. Clinical
evaluation is also via a stepwise procedure, beginning
with PK and PD studies followed by pivotal clinical tri-
Figure 2 Patent expiry for innovator biologic medicines in the EU. Source: Schellekens H et al., 2005 (1); Ledford H et al., 2007 (93)
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may sufﬁce. Similar efﬁcacy (equivalence designs) will
usually have to be demonstrated; however, non-inferior
study design may be considered if appropriately justiﬁed.
Safety data should be obtained in a sufﬁcient number of
patients, preferably in a comparative design. Prelicensing
safety data obtained from clinical trials can be expected
to detect frequent and short-term adverse events⁄reac-
tions; however, additional postmarketing monitoring of
an SBP will be necessary. Immunogenicity should be
investigated preauthorisation in humans.
Extrapolation of efﬁcacy and safety data to other indi-
cations may be possible if certain prerequisites are met,
e.g. the clinically relevant mode of action and⁄or
involved receptor(s) are the same, and no unique⁄addi-
tional safety issues are expected for the extrapolated indi-
cation(s).
The WHO is also the coordinating authority responsi-
ble for assigning international non-proprietary names
(INN) to identify pharmaceutical substances (28). In Sep-
tember 2006, the WHO recommended against introducing
distinctive INNs to indicate a biosimilar product, but
acknowledged that INNs should not be relied upon as the
only means of product identiﬁcation for biologicals nor
as the sole indicator of product interchangeability (29).
This has been incorporated into current guidelines and
the WHO recognises that National Regulatory Authori-
ties (NRA) need to deﬁne interchangeability and substitu-
tion of RBP with SBP and labelling and prescribing
information. The WHO recommends that the SBP should
be clearly identiﬁable by a unique brand name, which
should be stated alongside the INN (27). Furthermore,
provision of the lot number is essential and critical for
traceability in cases where problems are encountered. Pre-
scribing information should be as similar as possible to
that of the RBP, except for product-speciﬁc aspects, and
if the RBP has fewer indications related text may be omit-
ted. The NRA may choose to mention the SBP nature of
the product and the studies that have been performed
with the SBP and⁄or to include instructions for the pre-
scribing physician on how to use SBP products (27).
Other regulatory agencies in the world
In June 2006, the Australian Therapeutic Goods Admin-
istration adopted the European guidelines for registration
and approval of biosimilars – allowing for the registra-
tion of a biosimilar medicine on the basis of the evalua-
tion of an abbreviated quality and clinical dossier (30).
In the middle and near East, ongoing discussions have
utilised EMA guidelines as the basis for recommenda-
tions (31). The same is true of Canada, who in March
2010 published revised submission requirements for ‘sub-
sequent entry biologics’ (SEB) that largely follow EMA
guidelines (32). Non-Canadian-licensed innovator prod-
ucts may also constitute the reference product, providing
that the sponsor demonstrates a link to a biologic drug
authorised in Canada to which the SEB will be subsequent
(33). The Japanese Ministry of Health, Labour and Wel-
fare issued guidelines for the approval of biosimilars in
March 2009 (34). This process is separate to that for
conventional chemical generic drugs, with a review pro-
cess and data requirements more akin to those for new
drugs (34, 35). Biosimilar products should be clearly
identiﬁed by brand name, and non-proprietary names
should be followed by ‘kozoku-1’, meaning ‘follow-on-1’,
and so on (34, 35). In October 2009, Japan approved a
somatropin human growth factor biosimilar (36).
Oncology⁄ haematology biosimilars approved in
Europe
Erythropoiesis-stimulating agents
Erythropoiesis-stimulating agents (ESAs) up-regulate red
blood cell production and are indicated for the treatment
of symptomatic anaemia in adult cancer patients with
non-myeloid malignancies receiving chemotherapy. Two
epoetin alfa (recombinant erythropoietin) products (Epo-
gen
  (Amgen, Thousand Oaks, CA, USA) and Procrit
 
(Centocor Ortho Biotech, Horsham, PA, USA)) received
marketing approval in the United States in 1989. A third
innovator epoetin alfa product Erypo
 ⁄Eprex
  (Janssen-
Cilag GmbH; Baar, Switzerland) is approved in Europe;
ESAs are among the most widely used biologics (4). Two
biosimilar epoetins were the ﬁrst ‘oncology’ biosimilars
to receive European marketing approval utilising the
‘Similar Biological Medicinal Product’ application (5). In
both cases, the comparability exercise was performed in
patients with anaemia associated with chronic renal fail-
ure, using epoetin alfa (Eprex
 ) as the reference product.
Supportive data from single-arm studies in patients with
CIA were supplied for both products. It is particularly
interesting to note that the data presented for approval in
each of these two cases varied because of the rapidly evolv-
ing procedures for biosimilar approval during this period.
Clinical PD data were not included in the dossier pre-
sented for SB309 epoetin zeta (37, 38), as this was not
required under guidelines at the time; whereas PD data
from healthy volunteers formed part of the comparability
exercise for the approval of HX575 epoetin alfa (39–41).
SB309 epoetin zeta and HX575 epoetin alfa are single mol-
ecules licensed to multiple marketing authorisation holders
and marketed under several different names (Table 1).
A recent assessment of the similarity of SB309 high-
lighted necessary caveats in the assessment of similarity
in biosimilars (42). The EMA recommends that similarity
of potency to the innovator product is established within
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pean Pharmacopeia as 80–125% (error limits 64–156%)
for an in vivo bioassay. Thus, despite satisfying this
requirement, differences in potency of biological products
are probable. In the case of SB309, bioactivity (hence
potency) has been shown to be 10% lower compared
to the reference product epoetin alfa (Eprex
 ) in patients
with renal anaemia (42).
Granulocyte colony-stimulating factor
More recently, granulocyte colony-stimulating factor
(G-CSF) ﬁlgrastim biosimilars have received approval;
XM02 in September 2008 (43–46), EP2006 in February
2009 (47, 48) and PLD108 in June 2010 (49). Filgrastim
is a widely used biologic, over 7.7 million patients have
been exposed to the innovator product Neupogen
 
(Amgen, Thousand Oaks, CA, USA) since it received
marketing approval in 1991 (50). In the EU, ﬁlgrastim is
indicated in adults and children to shorten the duration
of neutropenia and reduce the incidence of febrile neu-
tropenia following receipt of cytotoxic chemotherapy
(51). It is also used to aid delivery of chemotherapy to
maintain dose intensity and to support dose-dense che-
motherapy (51, 52). Filgrastim is also indicated to mobi-
lise peripheral blood progenitor cells (PBPC) in both
cancer patients and healthy donors and to support
engraftment and neutrophil recovery after stem cell
transplantation (51). Outside the oncology setting, ﬁlgra-
stim is indicated for the treatment of severe chronic neu-
tropenia (51, 53, 54) and to maintain neutrophil counts
or reverse neutropenia in patients infected with human
immunodeﬁciency virus (51).
The comparability exercise for approval of the biosimi-
lar ﬁlgrastim products XM02, EP2006 and PLD108 was
conducted using ﬁlgrastim (Neupogen
 ) as the reference
product (Table 1). XM02 is a single molecule licensed to
multiple marketing authorisation holders and marketed
under several different names (43–46). In accordance with
EMA guidelines, comparability was assessed in a single
indication for which Neupogen
  is approved for the
reduction of chemotherapy-induced neutropenia (CIN).
Efﬁcacy was assessed in a comparative study in breast can-
cer patients at high risk of CIN, and supportive studies
provided safety data from CIN patients with lung cancer
and non-Hodgkin lymphoma. The biosimilar ﬁlgrastim
EP2006 is also a single molecule licensed to two marketing
authorisation holders and marketed under different names
(47, 48). In contrast to XM02, the comparable efﬁcacy of
EP2006 was established on the basis of PK and PD studies
in healthy adults, with a single-arm, non-comparative
study in patients at high risk of CIN with breast cancer
providing supportive safety data. PLD108 is a single mole-
cule licensed to a single marketing authorisation holder
(49). Comparability with the reference product ﬁlgrastim
(Neupogen
 ) was assessed in breast cancer patients at
high risk of CIN.
Biosimilars in oncology practice
Previous reports on biosimilars raised several issues sur-
rounding their introduction into clinical practice (3, 9,
10, 55). Given that biosimilar agents are now approved
in the EU, these issues can be discussed more compre-
hensively on the basis of published data and regulatory
documents. Issues speciﬁc to the introduction of the ﬁrst
biosimilar ESAs have been reviewed elsewhere (7). We
would like to focus on biosimilars in oncology practice,
where they are not used simply for the replacement of
hormones (e.g. growth hormones, insulin) or the treat-
ment of renal insufﬁciency (i.e. erythropoietin); but as
supportive therapy for immunosuppressed patients
receiving multiple cycles of cytotoxic therapy, or for
healthy stem cell donors who obtain no direct therapeu-
tic beneﬁt from treatment.
In general, oncologists should be aware that the terms
‘biosimilar’, ‘similar biotherapeutic product’, ‘subsequent
entry biologic’ or ‘follow-on biologic product’ refer to
the same type of product. Furthermore, it is important
to have a detailed knowledge of the characteristics of
these products, including extrapolation, substitution,
labelling, traceability, safety and immunogenicity. In the
following sections, we will give an overview of these key
points for each biosimilar product.
Table 1 Overview of oncology⁄haematology biosimilars licensed in
Europe
Molecule INN Brand name
Biosimilar erythropoietins
HX575 Epoetin alfa
1 Abseamed
  (39)
Binocrit
  (40)
Epoetin alfa Hexal
 (41)
SB309 Epoetin zeta
2 Retacrit
  (37)
Silapo
  (38)
Biosimilar G-CSFs
XM02 Filgrastim
3 Tevagrastim
  (43)
Ratiograstim
  (44)
Filgrastim ratiopharm
  (46)
Biograstim
  (45)
EP2006 Filgrastim
4 Zarzio
  (47)
Filgrastim Hexal
  (48)
PLD108 Filgrastim Nivestim
  (49)
1Single molecule HX575 licensed to multiple marketing authorisation
(MAA) holders.
2Single molecule SB309 licensed to multiple MAA holders.
3Single molecule XM02 licensed to multiple MAA holders.
4Single molecule EP2006 licensed to multiple MAA holders.
G-CSF, granulocyte colony-stimulating factor; INN, international non-
proprietary name.
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Extrapolation involves the approval of a drug for indica-
tions for which it has not been evaluated in clinical trials
(3). For the ﬁlgrastim biosimilars XM02, EP2006 and
PLD108, extrapolation from data in healthy adults and
CIN has allowed approval in all indications of the refer-
ence product (18, 23, 43–49). Although fully compliant
with current guidelines, extrapolation of data from one
indication to another has raised some concerns, particu-
larly with regard to the use of biosimilar ﬁlgrastim for
PBPC mobilisation and transplantation (56). In the
European Public Assessment Reports (EPARs) for
XM02, PBPC mobilisation was highlighted by the EMA
as an ‘area of uncertainty’, because it is not known
whether efﬁcacy in CIN can be fully extrapolated to
PBPC mobilisation (43–46). Following discussions with
the EMA, XM02 was approved with routine pharmaco-
vigilance for PBPC mobilisation (43–46). The risk-man-
agement plan for EP2006 speciﬁed additional follow-up
of healthy adults who participated in a phase I study
and 5-year follow-up of healthy stem cell donors in
cooperation with aphaeresis centres (47, 48). Similarly,
potential risks to healthy stem cell donors were acknowl-
edged in postapproval commitments for PLD108, which
included plans for targeted questionnaires and long-term
data collection, in addition to routine pharmacovigilance
(49). The European Group for Blood and Bone Marrow
Transplantation, however, advised against use of biosimi-
lar G-CSFs in unrelated healthy stem cell donors until
efﬁcacy and safety data have been collected in clinical
trials in the autologous setting, encompassing an ade-
quate number of stem cell mobilisation procedures with
adequate follow-up (57).
No experience concerning extrapolation to special
patient populations has been reported, as the biosimilar
ﬁlgrastim products XM02, EP2006, and PLD108 have
not been administered to children, patients with renal or
hepatic insufﬁciency or patients with acute myeloid
leukaemia (43–49).
Substitution in the EU
Substitution of one product with another that has the
same INN, by the pharmacist, is common practice with
generic drugs, but is not appropriate with biologics. This
has been clariﬁed by several European institutions and
agencies, including the EMA, which advises that the
decision to treat a patient with a reference or biosimilar
medicine should be taken following the opinion of a
qualiﬁed healthcare professional (8). As a consequence of
their complexity, automatic substitution of biologics
could give rise to different clinical consequences
and should be ruled out for reasons of patient safety
(9, 58).
Measures to prevent automatic substitution (dispensing
of generic drugs in place of prescribed innovator prod-
ucts by pharmacists without the knowledge or consent of
the treating physician (3)) are already in place in several
European countries, and other countries have taken steps
to limit or prohibit substitution of innovators with bio-
similars (Table 2). Substitution is also the subject of
debate in other regions: in July 2010 Health Canada sta-
ted that it does not support automatic substitution of an
SEB for its reference biologic drug as differences in man-
ufacturing over time may lead to changes that affect
drug products; Health Canada (59) therefore recom-
mends that physicians make only well-informed decisions
regarding therapeutic interchange. In the Middle East, it
has been recommended that products should be clearly
identiﬁed as biosimilars on the label (31).
Labelling
In order to maintain current standards of patient safety
regarding the use of biologic agents, it has been sug-
gested that distinct brand names, together with an
adapted summary of product characteristics (SmPC), are
used to identify both innovator and biosimilar agents
(6). Both biosimilar ESAs and G-CSFs have distinct
brand names. The SmPC for biosimilar epoetin alfa and
epoetin zeta include data from the reference product
Eprex
  SmPC; no biosimilar data are provided and,
except for mention of the brand name, it is not clear that
the product being described is a biosimilar (60–64). The
SmPC for the biosimilar ﬁlgrastim products XM02,
EP2006, and PLD108 present data from the SmPC of
the reference product Neupogen
 . Comparability studies
to a ‘reference product’ are mentioned, giving some indi-
cation that the product being described is a biosimilar;
however, biosimilar data are not presented and extrapo-
lated indications are not identiﬁed as such (65–71).
Healthcare professionals who are unfamiliar with the
regulatory process for biosimilars may not be aware that
the majority of the product information presented is not
derived from the product under consideration.
Traceability
The traceability of biologics, including biosimilars, is
important, as all these products have differences and
biosimilars are not identical to innovators. The exact
product prescribed should therefore be identiﬁed and
identiﬁable to enable accurate pharmacovigilance (6). In
line with several other national regulatory authorities
(30,31,35) and the WHO (27), the EMA requests that the
speciﬁc medicinal product given to the patient should be
clearly identiﬁed (5). In oncology⁄haematology, the bio-
similar G-CSFs have the INN ﬁlgrastim, the same as the
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law prohibits automatic substitution of innovators with generics
Country, Regulation (Year regulation came into force)
Speciﬁc
to biologics?
No automatic substitution allowed
France 2006 In 2006 French Law (LOI no 2006-3062, article 11) prohibited automatic substitution of
biosimilar products (75).
Yes
Germany 2008 The automatic substitution of biologics is not permitted in Germany. In January 2008,
German Social Law (Rahmenvertrag 20080117, § 129) indicated that pharmacists are
obliged to prescribe a generic product when available, and that physicians must actively
prohibit automatic substitution when prescribing, however, this does not apply to
biologics (76)
No
Greece 1976 & 1993 Greek Law (ND 96⁄1973 – Article 13, section 3) states that pharmacists are obliged to
provide the exact pharmaceutical products mentioned in a medical prescription and are
absolutely prohibited from substituting them with other pharmaceutical products (77).
This is reinforced by the Greek Code of Ethics for Pharmacists (PD 340⁄1993 - Article 23),
which states that pharmacists are not at liberty to substitute the pharmaceutical
products stated in a prescription with any other product (78).
No
Italy 2007 Based on a note from the Ministry of Health, the Italian Council of State issued opinion
(n.3992.07) stating that biosimilars cannot be substituted (79).
Yes
Slovenia 2008 Slovenian Medical Society guidelines prohibit the substitution of biologics, any medicinal
product should be approved for substitution by the Slovenian Medical Society (80).
Yes
Spain 2007 In 2007, the Spanish Health Agency (Ministerio De Sanidad Y Consumo) stated that
biologics as not substitutable - ORDEN SCO⁄2874⁄2007 (81).
Yes
Sweden 2007 In 2007, the Swedish Medicines Agency (MPA) issued a statement saying that biologics
are not interchangeable and are not recommended for substitution (82).
Yes
UK 2010 (ongoing) At present there is no automatic substitution of biologics in the United Kingdom, if the
physician prescribes by brand, this is what must be given. There is ongoing consultation
about the introduction of automatic substitution. The Department of Health (DoH) and
the Association of the British Pharmaceutical Industry (ABPI) have proposed to
Medicines and Healthcare products Regulatory Agency (MHRA) that biologics⁄biosimilars
should be exempt from automatic substitution and that biologics should only be
substituted with prescribing physician’s knowledge and prior consent. The MHRA has
stated that it is best practice to prescribe by brand name to ensure traceability (83).
Yes
Automatic substitution must be actively prohibited by the physician
Czech Republic 2008 In January 2008, Czech Drug Law (No 378⁄2007, § 83, article 2) was updated to state
that automatic substitution of any originator product with a generic must be actively
prohibited by the physician (84).
No
Ofﬁcial list stating which products cannot be substituted
Denmark 2010 Biosimilars can be substituted for each other, but not for reference products in the
substitution lists issued by the Danish Medicines Agency (DKMA; (85)).
Yes
Finland 2009 The Finnish Regulatory Agency (FINMEA) states that products given parenterally are not
substitutable (86).
No
Hungary 2009 Biosimilar products are absent from the positive substitution lists issued by the
Hungarian National Institute of Pharmacy, thereby preventing their automatic
substitution (87).
Yes
Norway 2010 In Norway, all pharmaceuticals that are regarded as generics or therapeutically equivalent
should be put on an automatic substitution list. Although ﬁlgrastim was initially
considered for substitution, in July 2010 the Norwegian Medicines Agency (NOMA)
announced that until further notice ﬁlgrastim will be taken off the substitution list (88).
Biosimilars are absent from the October 2010 substitution lists (89).
Yes
Slovakia 2008 Biosimilar products are absent from positive substitution lists published by The Slovakian
Ministry of Health (90).
Physicians obliged to prescribe by brand name
Austria 2005 Austrian Medicines Law (AMG § 10 section 8) recognises that biosimilars are not
generics. Physicians are obliged to prescribe by brand name and to look for the
cheapest but best medicines for their patients therefore there is no obligation to
substitute biologics and this responsibility lies with the physician (o ¨konomische
Verschreibung, RO ¨ F 2005; (91)).
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ESAs that used the same reference innovator product
(Eprex
  epoetin alfa) have been assigned two different
INNs – with one product receiving the same INN as the
innovator (39–41) and another being assigned a different
INN epoetin zeta (37, 38).
Safety and immunogenicity
Immunogenicity is the most important safety issue con-
cerning all biosimilar products (1, 72, 73). Analytical
tests and clinical trials detect many, but not all, potential
immunogenic responses; so postmarketing commitments
and pharmacovigilance are critical (1, 73). In oncol-
ogy⁄haematology, biosimilar ESAs have additional post-
marketing studies in their risk-management plan to
address safety concerns such as pure red cell aplasia,
thrombotic vascular events and tumour growth potential,
as well as to monitor potential off-label subcutaneous
use in renal anaemia patients (37–41).
In contrast, the postmarketing programme for biosimi-
lar G-CSFs differs between products. Routine risk man-
agement and a signal detection procedure for
immunologic events are proposed for the biosimilar ﬁl-
grastim XM02, although this is the ﬁrst product for
which extrapolated indications were granted (43–46). This
risk-management plan was approved on the basis that
immunogenicity data from comparative clinical trials
indicated no signiﬁcant group differences between cancer
patients treated with biosimilar ﬁlgrastim and patients
treated with the innovator reference ﬁlgrastim (Neupo-
gen
 ). Length of follow-up is important when assessing
immunogenicity; however, the duration of follow-up for
patients and healthy volunteers who received XM02 is
not clearly stated in the product EPARs (23). For the
biosimilar ﬁlgrastim EP2006, a more extensive postmar-
keting programme is described, including a phase IV
study, and cooperation with the severe chronic neutrope-
nia registry, as well as aphaeresis centres to investigate its
use for mobilisation in healthy stem cell donors (47, 48).
Some safety and potential immunogenicity differences
between the biosimilar ﬁlgrastim PLD108 and its refer-
ence product (Neupogen
 ) were reported in the product
EPAR (49). A higher incidence of bone pain and myalgia
was observed with PLD108, this is addressed in the prod-
uct label where bone pain is described as ‘common’ for
the reference product and ‘very common’ for PLD108
(71). As a potential higher risk of immunogenicity in indi-
viduals treated with PLD108 could not be excluded (a
low number of patients treated with PLD108 had G-CSF
antibodies), the risk-management programme proposed
includes plans for targeted questionnaire follow-up of
potential immunogenicity in addition to routine pharma-
covigilance. Other postapproval commitments for
PLD108 include targeted follow-up through the severe
chronic neutropenia registry, specialised follow-up for
long-term data and cooperation with international trans-
plant centres.
In the United Kingdom, the Medicines and Healthcare
products Regulatory Agency have marked the biosimilar
ESA products epoetin alfa and epoetin zeta, and the bio-
similar ﬁlgrastim products XM02, EP2006 and PLD-108
with a black triangle, which indicates these products
should be intensively monitored in order to conﬁrm their
risk⁄beneﬁt proﬁle (74). It should be noted that this
scheme is not limited to biologics, but applies to all new
medicinal products for which limited safety data raises
concerns; such triangles would not be applied to a stan-
dard generic.
Summary and outlook
The introduction of biosimilars is a new development;
because of inherent differences between biosimilars and
innovator compounds, biosimilars undergo more thor-
ough investigation than generic small molecule pharma-
ceuticals – but data and exposure remain limited
compared with innovators. The regulation of biosimilars
is a constantly evolving process, and the EMA has the
most developed regulatory system for biosimilars. In the
near future, the number of biosimilar medicines is likely
to grow quite rapidly (Fig. 2), with several ﬁrst-genera-
tion agents coming off-patent in the EU by 2014. In the
oncology setting, we could see the development of bio-
similar interferons and possibly, depending on regulatory
developments, monoclonal antibodies such as anti-EGFR
and anti-CD20. Regulatory processes will undoubtedly
be reﬁned and adapted as experience with biosimilar
agents grows.
Biosimilars bring additional prescribing options; how-
ever, it is important for healthcare professionals to know
the differences between these agents and a standard gen-
eric. Information on biosimilars remains limited, espe-
cially among oncologists and haematologists, and needs
to be addressed in detail. In contrast to other biosimilars,
in this therapeutic area products are given to immuno-
suppressed patients (who are at higher risk of complica-
tions) and to healthy stem cell donors (who derive no
therapeutic beneﬁt) thereby requiring the prescribing
physician to have a more comprehensive knowledge of
biosimilars.
The ﬁrst step involves accurate naming of the product
class and particularly the speciﬁc product, as some bio-
similar agents have already been given the same INN as
their reference product. Furthermore, extrapolation of
indication leading to authorisation plays a major role,
particularly in mobilisation procedures. In the next step,
the product prescribed (innovator or biosimilar) should
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normally involves multiple cycles of therapy. Substitution
(of innovator for biosimilar or between biosimilars)
should be avoided as much as possible by describing
brand name and INN to ensure traceability. While some
EU countries already had regulations in place to prevent
automatic substitution of medicinal products, many more
have acted speciﬁcally to prevent the automatic substitu-
tion of biologics. Special attention should be given to
labelling and the product SmPC, which sometimes pro-
vide information on the innovator (reference) product,
rather than the biosimilar product itself. Reporting com-
plications after treatment, especially long-term complica-
tions, becomes an important issue in patients treated
with complex protocols and multiple lines of therapy.
Physicians, pharmacists and patients should be aware of
both the new possibilities and the new challenges posed
by biosimilars.
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